Company Overview and News

 
Bellevue Gold continues to expand one of the highest-grade new gold discoveries in Australia

2018-09-04 proactiveinvestors.com.au
Bellevue Gold Ltd (ASX:BGL) Is progressing a unique opportunity to unlock the potential of one of Australia's historic high-grade gold mines, the Bellevue Gold Mine in Western Australia.
BGL

 
Bellevue Gold accelerates drilling at high-grade underground lode Viago

2018-08-28 proactiveinvestors.com.au
Bellevue Gold Ltd (ASX:BGL) has accelerated its diamond drilling efforts at the new Viago lode discovery at the Bellevue Gold Project in Western Australia.
BGL

 
Bellevue Gold’s ‘game plan is to keep on drilling’ after second high-grade discovery

2018-08-22 proactiveinvestors.com.au
Bellevue Gold Ltd (ASX:BGL) executive director Steve Parsons speaks to Proactive Investors about the gold company’s development of the historical Bellevue Gold Mine, as well as new high-grade discoveries made in recent drilling.
BGL

 
Bellevue Gold confirms deep gold discovery at WA project

2018-08-06 proactiveinvestors.com.au
Bellevue Gold Ltd (ASX:BGL) has confirmed a new gold discovery from recent drill results at its Bellevue project in Western Australia.
BGL

 
Bellevue Gold reveals maiden high-grade resource of 500,000 gold ounces

2018-08-01 proactiveinvestors.com.au
Bellevue Gold Ltd (ASX:BGL) has revealed a high-grade maiden resource of 1.9 million tonnes at 8.2 g/t gold for 500,000 ounces at its Bellevue Gold Project in Western Australia.
BGL DRG

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to ASX:BGL / BIGAIR GROUP LIMITED on message board site Silicon Investor.

OBGL - $5 Cash Buyout, Fact or Fiction OBGL - $5 Cash Buyout, Fact or Fiction OBGL - $5 Cash Buyout, Fact or Fiction GBGLF: Great Basin Gold Ltd. GBGLF: Great Basin Gold Ltd. GBGLF: Great Basin Gold Ltd.
BMR Gold /BGL-T BMR Gold /BGL-T BMR Gold /BGL-T BGLS (Manhattan Bagel Company) BGLS (Manhattan Bagel Company) BGLS (Manhattan Bagel Company)